Impact of correlation structure on sample size requirements of statistical methods for multiple binary outcomes: A simulation study
Clinical Trials · 2025
DOI: 10.1177/17407745241304706 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Trials, 2025. Verfasst von Kanako Fuyama und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
In randomized clinical trials, multiple-testing procedures, composite endpoints, and prioritized outcome approaches are increasingly used to analyze multiple binary outcomes. Previous studies have shown that correlations between outcomes influence their sample size requirements. Although sample size is an important factor affecting the choice of statistical methods, the power and required sample sizes of methods for analyzing multiple binary outcomes have yet to be compared under the influence of outcome correlations.
Methods
We conducted simulations to evaluate the power of co-primary and multiple primary endpoints, composite endpoints, and prioritized outcome approaches based on generalized pairwise comparisons with varying correlations, marginal proportions, treatment effects, and number of outcomes. We then conducted a case study on sample size using a clinical trial of a migraine treatment as an example.
Results
The correlations significantly affected the statistical power and sample size of composite endpoints. The power and sample size of co-primary endpoints remained relatively stable across different correlations, though their power declined substantially when treatment effects were opposite on some components or more than two components were present. While the correlations influenced the power and sample size of all methods assessed, their direction and degree of influence varied between methods. Notably, the method with the greatest power and smallest sample size also differed depending on the correlations. When the correlations were the same between arms, prioritized outcome approaches usually had higher power and smaller sample sizes than other methods.
Conclusions
Anticipated correlations and their uncertainty should be considered when selecting statistical methods. Overall, co-primary endpoints remain a reliable option for evaluating the superiority of all components, although they are unsuitable for assessing the balance between treatment effects pointing in different directions. Generalized pairwise comparisons offer a useful alternative to deal with multiple prioritized outcomes, often providing the smallest sample sizes when the correlation structures are shared between the arms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
- Faculty of Health Data Science, Juntendo University, Tokyo, Japan.
- Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Kanako Fuyama, Kentaro Sakamaki, Isao Yokota
Zitieren
APA
Fuyama, K., Sakamaki, K., Uemura, K., & Yokota, I. (2025). Impact of correlation structure on sample size requirements of statistical methods for multiple binary outcomes: A simulation study. Clinical Trials. https://doi.org/10.1177/17407745241304706
Vancouver
Fuyama K, Sakamaki K, Uemura K, Yokota I. Impact of correlation structure on sample size requirements of statistical methods for multiple binary outcomes: A simulation study. Clinical Trials. 2025. doi:10.1177/17407745241304706
BibTeX
@article{Fuyama2025,
author = {Fuyama, Kanako and Sakamaki, Kentaro and Uemura, Kohei and Yokota, Isao},
title = {Impact of correlation structure on sample size requirements of statistical methods for multiple binary outcomes: A simulation study},
journal = {Clinical Trials},
year = {2025},
doi = {10.1177/17407745241304706}
}
EUVIMED